Abstract. Mosapride citrate hydrate (mosapride) has been known to act as a 5-HT 4 agonist and to enhance gastric emptying. However, its mode of action, such as time course and dosage effect, on gastric emptying has not been clarified. This study aimed to clarify these points by the breath test using [1-
Introduction
5-Hydroxytryptamine (serotonin; 5-HT) has been known to be a neurotransmitter in the brain and the gut. The presence of 5-HT in the gastrointestinal tract has been demonstrated by immunohistochemical studies in enterochromaffin cells and in enteric neurons (1 -3) . Several 5-HT receptor subtypes have been identified in the gastrointestinal tract. These are located in nerves or on smooth muscle cells where they mediate a number of different actions (4, 5) .
Mosapride citrate hydrate (mosapride) has been known to act as a 5-HT 4 agonist and has been known to enhance gastric motility (6) . Seto et al. (7) reported that mosapride inhibited the gastric distension-induced visceromotor response in conscious rats, and this inhibitory effect of mosapride was mediated via activation of 5-HT 4 receptors and blockage of 5-HT 3 receptors by a major metabolite of mosapride (M1). Yoshida et al. (8) also reported that M1 possessed a potent 5-HT 3 receptorantagonistic property. Therefore, M1 would inhibit the gastric emptying. However, there were no detailed reports about the mode of action of mosapride and M1 on gastric emptying, including their effects on the time course of gastric emptying and dosage effect.
On the other hand, 13 C-breath tests have been developed recently as a nonradioactive alternative in clinical study. The 13 C-labeled urea breath test, in particular, has been widely employed clinically to monitor Helicobacter pylori infections. In addition, the [1-
13 C]octanoic acid breath test has been applied frequently in the clinical diagnosis of gastric-emptying disorder since it was first reported by Ghoos et al. in 1993 (9) . We recently reported a simple and non-invasive breath test for evaluating gastric emptying using [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetic acid (10) (10 -13) . Then, in this study we investigated the dosage effect of mosapride (5-HT 4 receptor agonist) and time course of the gastric emptying using the breath test with [1- 13 C] acetic acid. Moreover, the effect of M1 (5-HT 3 receptor antagonist) on the gastric emptying was also investigated.
Materials and Methods
The following animal studies were performed according to Guiding Principles for the Care and Use of Laboratory Animals approved by The Japanese Pharmacological Society.
Animals
Male Sprague-Dawley rats (200 -250 g) was purchased from SLC (Shizuoka) and kept for 1 week before the experiments in a room whose temperature and humidity were kept at 21°C ± 2°C and 55% ± 5%, respectively. The light and dark cycle was 12 h, and the light period was from 7:00 to 19:00.
Breath test
The breath test was performed according to the method reported by us (10) . In brief, the breath test system is composed of an animal chamber (desiccator, 2000 ml), pump (Masterflex L/S; Cole-Palmer Inst. Co., Court Vernon Hills, IL, USA) and breath sampling bag (Ohtsuka Pharmaceutical Co., Ltd., Tokyo). Collected 13 CO 2 air was measured with UBiT IR-300 and UBiT-AS10 (Ohtsuka Electronics Co., Ltd., Osaka).
Rats were placed in the chamber just after the oral administration of Racol (2.5 ml/kg, Nutrient formula; Ohtsuka Pharmceutical Co., Ltd.) containing [1- 13 C] acetic acid (16 mg/kg). Expired 13 CO 2 air was collected and measured at 5-min intervals until 70 min, followed by collection and measurement at 90 and 120 min after Racol administration. Expired 13 CO 2 air was collected for 1.5 min at each measured point. Ventilation volume was 150 ml/min.
Analysis of the gastric emptying
The measured values were presented as the Δ 13 CO 2 (‰). The maximum concentration (C max , ‰), the time taken to reach the maximum concentration (T max , min), and the area under the curve (AUC 120 min , ‰·min) were calculated using the Δ 13 CO 2 values.
Effect of mosapride on the gastric emptying
Mosapride was dissolved in the distilled water and administered orally (0.1 to 3 mg/kg, 5 ml/kg). The breath test was performed 30 min after mosapride administration. In the control rats distilled water was administered instead of mosapride (5 ml/kg).
In another experiment, mosapride at a dose of 30 mg/kg (5 ml/kg) was orally administered and the breath test was performed 30 min after its administration. In the control rats, distilled water was administered instead of mosapride (5 ml/kg).
Effect of GR113808 on the enhancement of the gastric emptying by mosapride
GR113808 suspended in distilled water was administered at a dose of 10 mg/kg (1 ml/kg, i.p.) 30 min before oral administration of mosapride at a dose of 3 mg/kg (5 ml/kg). The breath test was performed 30 min after mosapride treatment. In the control rats, distilled water was administered instead of GR113808 and mosapride.
Effect of M1 on the gastric emptying
M1 (19.2 and 64.1 mg/kg, 5 ml/kg) was dissolved in distilled water and orally administered. The breath test was performed 30 min after the administration. In the control rats, distilled water was administered instead of M1 (5 ml/kg). M1 of 19.2 and 64.1 mg/kg was equimolar to 30 and 100 mg/kg mosapride, respectively.
Agents
Mosapride citrate hydrate and M1 were kindly given to us by Dainippon Sumitomo Pharmaceutical Co., Ltd. [1-
13 C] acetic acid and Racol were purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA) and Ohtsuka Pharmaceutical Co., Ltd., respectively. GR113808 was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Statistical analysis
Results were represented as the mean ± S.E.M. Statistical analyses were performed by Student's t-test or Dunnett's multiple comparison method, and values of P < 0.05 were regarded as significant.
Results

Effect of mosapride on the gastric emptying
In the control rats, expired 13 CO 2 increased with time until 32.5 min when it peaked and decreased thereafter (Fig. 1) . C max and AUC 120 min values were 271.2‰ ± 7.5‰, 18627‰ ± 736‰·min, respectively (Table 1) . By the pre-treatment with mosapride, gastric emptying was dose-dependently enhanced (Fig. 1) . C max and AUC 120 min values were significantly increased at 1 mg/kg or over, but T max was not affected (Table 1) .
In another experiment to evaluate the effect of 30 mg/kg of mosapride, expired 13 CO 2 increased in with time until it peaked at 25.0 min and decreased thereafter in the control rats (Fig. 2) . C max and AUC 120 min values were 309.1‰ ± 34.7‰, 19051‰ ± 1444‰·min, respectively (Table 2) . Mosapride significantly inhibited the gastric emptying (Fig. 2) . C max and AUC 120 min values were also significantly decreased, but T max was not affected ( Table 2) .
Effect of GR113808 on the enhancement of the gastric emptying by mosapride
In the control rats, expired 13 CO 2 increased with time until it peaked at about 30 min and decreased thereafter (Fig. 3) . C max and AUC 120 min values were 299.2‰ ± 16.6‰, 22400‰ ± 356‰·min, respectively (Table 3 ). Mosapride at a dose of 3 mg/kg (5 ml/kg, p.o.), significantly enhanced the gastric emptying and C max value significantly increased as compared with the control (Table 3) . Pretreatment with GR113808 significantly attenuated the mosapride-induced increase of expired 13 CO 2 (Fig. 3) and C max value showed a tendency to decrease as compared with mosapride-administered rats (P < 0.10) ( Table 3) .
Effect of M1 on the gastric emptying
In the control rats, expired 13 CO 2 increased with time, peaking at about 30 min (Fig. 4) . C max and AUC 120 min values were 274.3‰ ± 13.4‰ and 18491‰ ± 715‰·min, respectively (Table 4) . Treatment with M1 significantly inhibited the gastric emptying at both doses of 19.2 and 64.1 mg/kg (Fig. 4) . C max value was significantly decreased at doses of 19.2 and 64.1 mg/kg and AUC 120 min Values represent the mean ± S.E.M. (n = 4). **P < 0.01: significant difference from the control. value at a dose of 64.1 mg/kg (Table 4) . T max value was not affected (Table 4) . Mosapride, selective 5-HT 4 receptor agonist, stimulates gastric motility and gastric emptying in animals and human (6, 18) and has been shown to enhance colonic motility and rectorectal and rectoanal reflexes in guinea Values represent the mean ± S.E.M. (n = 4). **P < 0.01: significant difference from the control.
+ P < 0.10: tendency to decrease as compared with mosapride citrate hydrate. pigs (19, 20) . In a clinical study, Ruth et al. (21) reported the efficacy of mosapride in the patients with gastroesophageal reflux disease from the finding that mosapride significantly improved total acid clearance time by enhancing gastric emptying.
In the present study, mosapride dose-dependently and significantly enhanced the gastric emptying at doses of 0.3 to 3 mg/kg. This action would be mediated through the 5-HT 4 receptor-agonistic action as reported by other researchers (6, 18, 21) . Sakamoto et al. (22) also reported that mosapride accelerated the delayed gastric emptying of high-viscosity liquids in a crossover study using the continuous real-time C breath test (BreathID System). This finding supports the present results using the same breath test system, although the precise methods were different from each other. In the present study, the pre-treatment with GR113808 significantly attenuated the enhancement of gastric emptying by mosapride. This finding strongly suggests the involvement of 5-HT 4 receptors in the enhancement of gastric emptying by mosapride.
Wang et al. (23) In the present study, a significant inhibition of gastric emptying was observed by mosapride at a dose of 30 mg/kg. If the 5-HT 4 receptor-agonistic action had a major effect on gastric emptying, gastric emptying at 30 mg/kg would be enhanced more than at a dose of 3 mg/kg, but the gastric emptying was significantly inhibited. The LD 50 value of mosapride was > 3000 mg/kg (cited from the Interview Form of Gasmotin). Therefore, the dose of 30 mg/kg seems not to be toxic. Indeed, no toxic symptom was observed in this study. In the clinic, 5 mg is administered orally three times a day. In the case of a barium enema, 20 mg is administered orally at once. Therefore, 30 mg/kg seems not to be a toxic dosage. Mosapride has been known to be metabolized to the M1. Yoshida et al. (26) reported that M1 possessed a potent 5-HT 3 receptor antagonist property. Indeed, M1 dosedependently inhibited gastric emptying. Mosapride at 30 mg/kg is equimolar to M1 at 19.2 mg/kg, suggesting that the inhibitory effect by mosapride may be caused at least in part by the 5-HT 3 receptor-antagonistic effect of M1. However, to clarify the inhibitory mechanism of gastric emptying by mosapride at 30 mg/kg, further study is needed.
In Rome III, functional dyspepsia is categorized into postprandial distress syndrome and epigastric pain. Postprandial distress syndrome is further divided into early satiation and postprandial fullness, which are closely related to gastric motility. Seto et al. (6) reported that mosapride was useful in alleviating functional dyspepsia-associated gastrointestinal symptoms via increase in pain threshold using the balloon gastric distension method to enable measurements of abdominal muscle contractions in conscious rats and that M1 also inhibited the gastric distension-induced visceromotor response. This finding shows the enhancement of adaptive relaxation (accommodation) by mosapride and suggests its usefulness for early satiation following the delay of gastric emptying. However, mosapride is also used in the therapy for postprandial fullness following the enhancement of gastric emptying. Therefore, the dual role of mosapride on gastric emptying observed in the present study may explain its clinical usefulness for the therapy of postprandial distress syndrome mentioned above.
In conclusion, mosapride showed dual roles on gastric emptying through a 5-HT 4 receptor-agonistic effect and a 5-HT 3 receptor-antagonistic effect. This dual role may explain the utility of mosapride for the therapy of postprandial distress syndrome.
